Related Experiment Videos

Diuretics for Preventing Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review and Meta-Analysis

Shin Kato1, Masato Koizumi2, Jun Nirei3

  • 1Department of Pediatrics, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan, shinkato2@gmail.com.

Neonatology
|July 9, 2026
PubMed

Insights

Diuretics do not prevent bronchopulmonary dysplasia (BPD) in preterm infants, according to current evidence. More research is needed to confirm their role and safety in BPD prevention strategies.

Area of Science:

  • Neonatal Medicine
  • Pediatric Pulmonology
  • Pharmacology

Background:

  • Bronchopulmonary dysplasia (BPD) remains a significant challenge in preterm infant care.
  • Previous randomized controlled trials (RCTs) have not established the efficacy of diuretics in preventing BPD.
  • Recent observational studies suggest a potential role for diuretics, necessitating an updated synthesis of evidence.

Purpose of the Study:

  • To evaluate the preventive effects of diuretics on bronchopulmonary dysplasia (BPD) in preterm infants.
  • To assess the safety profile of diuretic use in this vulnerable population.
  • To synthesize evidence from both randomized and non-randomized studies.

Main Methods:

  • Comprehensive literature search of MEDLINE, Embase, Cochrane CENTRAL, and CINAHL up to June 2025.
  • Inclusion of 40 studies (6 RCTs, 34 non-randomized studies) evaluating various diuretic classes, routes, doses, and durations.
  • Risk of bias assessment using RoB 2 and ROBINS-I; certainty of evidence graded by GRADE; meta-analysis using random-effects models.

Main Results:

  • RCTs did not demonstrate a preventive effect of diuretics on BPD, focusing mainly on short-term lung mechanics.
  • Meta-analysis revealed no significant effects of diuretics on death or BPD (RR, 1.10; 95% CI, 0.77-1.59) or mortality (RR, 0.44; 95% CI, 0.19-1.04).
  • Electrolyte abnormalities were not significantly increased (RR, 1.51; 95% CI, 0.81-2.83); however, non-randomized studies suggested potential BPD reduction, but with low to very low certainty of evidence.

Conclusions:

  • Current evidence does not confirm that diuretics prevent bronchopulmonary dysplasia (BPD).
  • The safety profile of diuretics appears favorable, but evidence quality is limited by small sample sizes and confounding factors.
  • Larger, adequately powered RCTs are essential to definitively explore the role of diuretics in BPD prevention.
Abstract

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Breathing01:05

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...